SDF-1 Binding Nucleic Acids for Specific Antagonism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack a specific antagonist for SDF-1 and effective treatments for diseases involving SDF-1 and its receptor CXCR4, as well as methods for detecting SDF-1.
Innovation Solution
Development of nucleic acid molecules that bind specifically to SDF-1, comprising specific core and stretch sequences, which can be used in pharmaceutical compositions, diagnostic means, and kits for treating and detecting SDF-1-mediated diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current methods are used for treating diseases involving SDF-1, then no specific antagonist is available, but this results in lack of effective treatment options
Solution Approach 1:
The patent uses nucleic acid molecules as intermediary substances that specifically bind to SDF-1, acting as a mediator between the therapeutic goal and the target protein. These nucleic acid antagonists serve as the missing specific antagonist mentioned in the contradiction, providing both availability and effectiveness simultaneously.
Solution Approach 2:
The invention changes the parameter of molecular interaction by introducing nucleic acid molecules with specific sequences that bind to SDF-1 with defined affinity constants. This parameter change enables specific antagonism where none existed before, resolving the contradiction between availability and effectiveness.
2Measurement precision
If no specific detection method for SDF-1 is available, then diagnostic capabilities are limited, but this results in inability to detect SDF-1-mediated diseases
Solution Approach 1:
The nucleic acid molecules serve as intermediary detection agents that specifically bind to SDF-1, enabling precise measurement and detection. This intermediary approach provides both the measurement precision and diagnostic versatility needed to overcome the stated contradiction.
3Adaptability or versatility
If general chemokine research is conducted without specific SDF-1 antagonists, then broad understanding is achieved, but this results in lack of targeted therapeutic intervention
Solution Approach 1:
The patent segments the broad chemokine research field by introducing specific nucleic acid molecules targeted at SDF-1. This segmentation allows simultaneous maintenance of broad research scope and achievement of targeted intervention specificity, resolving the contradiction between range and specificity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nucleic acid molecules effectively inhibit angiogenesis, neovascularization, inflammation, and metastasis, providing a therapeutic and diagnostic tool for SDF-1-related diseases such as diabetic retinopathy, cancer, and other conditions.
Implementation Method 1
an SDF-1 binding nucleic acid molecule... comprising in 5'->3' direction a first stretch of nucleotides, a core nucleotide sequence and a second stretch of nucleotides
Data Source
Figure 1
Figure 1
Figure 2A
AI summary
The present invention is related to a nucleic acid molecule, preferably binding to SDF-I, selected from the group comprising type A nucleic acid molecules, type B nucleic acid molecules, type C nucleic acid molecules and nucleic acid molecules having a nucleic acid sequence according to any of SEQ.ID.No. 142, SEQ.ID.No. 143 and SEQ.ID.No. 144.